Evidence map›Paper›PMID 32383387›Full record

ArticleAmerican journal of Alzheimer's disease and other dementias

Risk Factors for Cardiovascular Events in Patients on Antidementia Medications.

Meiqi He, James M Stevenson, Yuting Zhang, Inmaculada Hernandez

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of Alzheimer's disease and other dementias. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The Impact of Cognitive Impairment on Cardiovascular Disease.Journal of the American College of Cardiology · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Meiqi HeDepartment of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-6342-2011
James M StevensonDivision of Clinical Pharmacology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Yuting ZhangMelbourne Institute, Applied Economics and Social Research, Faculty of Business and Economics, University of Melbourne, Victoria, Australia.
Inmaculada HernandezDepartment of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
University of Pittsburgh · USJohns Hopkins University · USThe University of Melbourne · AU

Funding

Patient and System-Level Determinants of Oral Anticoagulation Use in Atrial FibrillationK01HL142847 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HERNANDEZ, INMACULADA · 2018 to 2022
$798k
NHLBI NIH HHS K01 HL142847
6 · The paper itself

Abstract

objectiveTo identify characteristics associated with an increased risk of cardiovascular events in patients diagnosed with Alzheimer disease (AD) and treated with antidementia medications.

methodsDemographics, diagnoses, and medication usage of 30 433 Medicare patients were analyzed using 2006 to 2013 claims data and a combined model of screening, ranking and stepwise logistic regressions to evaluate factors associated with composite outcomes of 6 cardiovascular events.

resultsIncidence rate of at least 1 cardiovascular event was 25.1%. Fifty-five factors were identified from the 10 381 candidate variables by the combined model with a c-statistic of 67% and an accuracy of 75%. Factors associated with increased risk of cardiovascular events include history of heart rhythm disorders, alteration of consciousness (odds ratio [OR]: 1.25; 95% confidence interval [CI]: 1.14-1.36), and usage of β-blockers (OR: 1.19; 95% CI: 1.13-1.27).

conclusionsClinicians should consider the increased risk of cardiovascular events in patients with AD with heart rhythm disorders and on β-blockers.

Indexed as

Adrenergic beta-AntagonistsAgedAged, 80 and overAlzheimer DiseaseArrhythmias, CardiacCardiovascular DiseasesFemaleHumansMaleMedicareOdds RatioRisk FactorsUnited StatesAdrenergic beta-Antagonistsantidementia therapycardiovascular eventclaimsdata miningMedicare

Identifiers

PMID32383387
PMCPMC7315406
OpenAlexW3023095763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.